KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Acquisitions (2016 - 2019)

Edwards Lifesciences (EW) has 6 years of Acquisitions data on record, last reported at $98.9 million in Q2 2019.

  • For Q2 2019, Acquisitions changed N/A year-over-year to $98.9 million; the TTM value through Sep 2020 reached $98.9 million, down 1.3%, while the annual FY2019 figure was $100.2 million, N/A changed from the prior year.
  • Acquisitions reached $98.9 million in Q2 2019 per EW's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Acquisitions topped out at $320.8 million in Q3 2015 and bottomed at -$200000.0 in Q1 2017.
  • Average Acquisitions over 4 years is $70.3 million, with a median of $11.5 million recorded in 2015.
  • Peak YoY movement for Acquisitions: tumbled 33.91% in 2016, then skyrocketed 1321.05% in 2017.
  • A 4-year view of Acquisitions shows it stood at $11.5 million in 2015, then crashed by 33.91% to $7.6 million in 2016, then surged by 1321.05% to $108.0 million in 2017, then dropped by 8.43% to $98.9 million in 2019.
  • Per Business Quant database, its latest 3 readings for Acquisitions were $98.9 million in Q2 2019, $1.3 million in Q1 2019, and $108.0 million in Q4 2017.